SAN FRANCISCO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/CureIsInSight?src=hash" target="_blank"gt;#CureIsInSightlt;/agt;–Glaucoma Research Foundation launches The Catalyst for a Cure Vision Restoratio…
Author: Business Wire
Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics
VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has entered into a licensing agreement that grants Iconic Ther…
Delta Dental of Tennessee Introduces DeltaVision in Partnership with VSP Vision Care
NASHVILLE, Tenn.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/DeltaVisionTN?src=hash" target="_blank"gt;#DeltaVisionTNlt;/agt;–Delta Dental of Tennessee launches DeltaVision in partnership with VSP.
FDA Approves Broadened Indication for XEOMIN® (IncobotulinumtoxinA) as First-Line Treatment for Blepharospasm (Involuntary Blinking) in Adult Patients
RALEIGH, N.C.–(BUSINESS WIRE)–Merz Americas announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA).
Livionex Pharma Raises $4 Million Series A at a $180 Million Valuation
SAN FRANCISCO–(BUSINESS WIRE)–Livionex Pharma Raises $4 Million Series A at a $180 Million Valuation
Tilak Healthcare Announces Exclusive Partnership for Co-Promotion with Novartis France
PARIS–(BUSINESS WIRE)–Tilak Healthcare, a pioneering video game studio specializing in mobile medical games for patients with chronic diseases, announces an exclusive co-promotion partnership with Novartis France for OdySight, its first clinically va…
Global Markets & Technologies for Optical Coherence Tomography (OCT) 2017-2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Markets and Technologies for Optical Coherence Tomography (OCT)” report has been added to ResearchAndMarkets.com’s offering. Growth factors include technological advancement in OCT products, adoption of OCT systems in different application areas and strong investment in R&D activities by key market players, such as CarlZeiss Meditec Inc., Abbott and Topcon Medical Systems Inc., among others. Within the context of this report, the global markets and techn
Ocular Therapeutix™ Reports First Quarter 2019 Financial Results and Business Update
BEDFORD, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target=&…
The Global Market for Ophthalmic Lasers, 2019 to 2024 – Highest Revenues Expected for Refractive Error Corrections – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Lasers Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering. The ophthalmic lasers market is expected to register a CAGR of 4.9%, over the forecast period. Factors that are responsible for the growth of this market include high prevalence of ophthalmic disorders, increasing initiatives to control visual impairment, and increasing regulatory approvals for ophthalmic lasers. FDA is aware that there
Ophthalmology Drug and Device Market – Growth, Trends, and Forecast (2019 – 2024) – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmology Drug and Device Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering. The ophthalmology drug and device market is expected to witness a CAGR of 5.3% during the forecast period. Certain factors that are driving the growth of the market include demographic shifts, the impact of the prevalence of eye disease, technological advancements in the field of ophthalmology, and a rising geriatric populat
BioTime Reports First Quarter 2019 Financial Results and Provides Business Update
ALAMEDA, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24BTX&src=ctag" target="_blank"gt;$BTXlt;/agt; lt;a href="https://twitter.com/hashtag/AMD?src=hash" target=&quo…
NovaBay Pharmaceuticals Reports First Quarter 2019 Financial Results
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, reports financial results for the three months end…
Noveome Biotherapeutics, Inc. Announces Publication of Further Preclinical Results Supporting the Neuroprotective Properties of ST266 in Retinal Ganglion Cells
PITTSBURGH–(BUSINESS WIRE)–Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, today announc…
Aerpio Reports First Quarter 2019 Financial Results and Provides Business Update
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the first…
Kala Pharmaceuticals Reports First Quarter 2019 Financial Results
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Deliv…
2019 Study on Myopia in the United States: Market Insights, Epidemiology and Forecast, 2017-2028 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Myopia – US Market Insights, Epidemiology and Market Forecast – 2028” drug pipelines has been added to ResearchAndMarkets.com’s offering. This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Myopia in the United States. The report provides the current treatment practices, emerging drugs, the market share of the individual therapies, the current and forecasted market size of Myopia fr
Takeda Simplifies Portfolio and Accelerates Deleveraging Through Two Divestitures
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into agreements to divest its Xiidra® (lifitegrast ophthalmic solution) 5% product (“Xiidra®”) to Novartis and its T…
Glaukos Corporation Announces First Quarter 2019 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies desig…
Retinopathy of Prematurity: 2019 Pipeline Insights – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Retinopathy of Prematurity – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. The report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Retinopathy of Prematurity development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmenta
IVERIC bio Reports First Quarter 2019 Financial and Operating Results
NEW YORK–(BUSINESS WIRE)–IVERIC bio today announced financial and operating results for the first quarter ended March 31, 2019 and provided a business update.